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Introduction: Agitation in children and adolescents in the emergency department (ED) can be 
dangerous and distressing for patients, family and staff. We present consensus guidelines for 
management of agitation among pediatric patients in the ED, including non-pharmacologic methods and 
the use of immediate and as-needed medications.
Methods: Using the Delphi method of consensus, a workgroup comprised of 17 experts in emergency 
child and adolescent psychiatry and psychopharmacology from the the American Association for 
Emergency Psychiatry and the American Academy of Child and Adolescent Psychiatry Emergency Child 
Psychiatry Committee sought to create consensus guidelines for the management of acute agitation in 
children and adolescents in the ED.
 
Results: Consensus found that there should be a multimodal approach to managing agitation in the 
ED, and that etiology of agitation should drive choice of treatment. We describe general and specific 
recommendations for medication use.
Conclusion: These guidelines describing child and adolescent psychiatry expert consensus for the 
management of agitation in the ED may be of use to pediatricians and emergency physicians who are 
without immediate access to psychiatry consultation. [West J Emerg Med. 2019;20(2)409–418.]
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INTRODUCTION
Background
Agitation and aggression in children and adolescents 
in the emergency department (ED) can be dangerous and 
distressing for patients, families and staff.1 Agitation and 
aggression can disrupt care, cause injury, or necessitate 
use of physical restraint. Of youth presenting to the ED 
for psychiatric care, 6-10% require restraint.2-3 At least 30 
children in the United States (U.S.) have died in restraint-
related incidents, which has led to regulations limiting the use 
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Population Health Research Capsule
What do we already know about this issue?
Pediatric agitation in the emergency 
department (ED) is both prevalent and 
challenging with no existing standard, 
despite the need for careful multidisciplinary 
evaluation and management.
What was the research question?
Can an evidence-based, consensus guideline 
be developed for the management of 
pediatric agitation in the ED?
What was the major finding of the study?
Evidence-based, expert consensus guidelines 
for management were developed including 
etiology-driven treatment strategies.
How does this improve population health?
Standardizing pediatric agitation 
management in the ED supports consistent 
and evidence-based care for patients and 
staff at risk for injury and negative outcomes.
of restraint to emergencies where least restrictive options have 
been exhausted.4-5 There is little guidance or standardization 
toward use of less restrictive options, especially medications, 
to manage agitation and avoid restraint. 
There are no randomized controlled trials, expert consensus 
guidelines, or comparative studies of medication efficacy or 
safety in the ED setting. A survey of emergency physicians 
(EP) regarding pro re nata (as needed) (hereafter referred to 
as STAT/PRN) medications commonly used for agitation, and 
review papers providing recommendations for medication use, 
all emphasize use of first- and second-generation neuroleptics, 
benzodiazepines, and mood stabilizers.2,6-9 These are largely 
inspired by consensus guidelines for treatment of agitated adults 
or pediatric outpatients with chronic aggression.10-12 Symptoms 
and triggers that underlie agitation in the ED may be different 
from those that underlie chronic aggression among outpatients.13 
A small number of studies have examined the use of 
STAT/PRN medications for acute agitation in psychiatrically 
hospitalized youth. There is only one randomized, placebo-
controlled study of STAT/PRN medication for acute agitation, 
which found no difference between diphenhydramine vs 
placebo.14 Intramuscular (IM) administration (of either 
diphenhydramine or placebo) was significantly more effective 
than by mouth (PO) administration. A retrospective study of 
STAT/PRN medications in 49 psychiatrically hospitalized 
youth reported antihistamines were used most commonly, 
followed by neuroleptics and sedative-hypnotics.15 Only 
32% of all PRNs were clearly effective on chart review. 
Benzodiazepines and neuroleptics were equally efficacious, 
and IM administration was significantly more effective than 
PO administration across medication classes. 
A retrospective study of STAT/PRN medications among 
psychiatrically hospitalized youth found that olanzapine was 
more likely than lorazepam or chlorpromazine to produce a 
“settling effect” within 30 minutes or less; all were generally 
well tolerated, although the authors noted that a small number 
of youth experienced paradoxical agitation with lorazepam.16 
Two case-controlled, retrospective, chart-review studies have 
assessed the relative efficacy of IM ziprasidone, compared 
to other IM neuroleptics, in psychiatrically hospitalized 
adolescents. The first compared IM ziprasidone to IM 
olanzapine; there was no significant difference in efficacy, 
although ziprasidone subjects received significantly more 
emergency medications.17 A second compared the combination 
of IM haloperidol with IM lorazepam and IM ziprasidone. 
There was no significant difference found in restraint duration, 
use of STAT/PRN medications, or vital sign changes.18
Importance
These studies have limited generalizability to STAT/PRN 
use of these medications for acute agitation or aggression 
in ED settings. Without evidence-based or expert consensus 
guidelines to direct decision-making, physicians in the ED 
setting typically use medications with which they are most 
comfortable, although these may not be the most effective or 
safest choice with significant variance in practice.2,6  
Goals of Investigation
We aim to present consensus guidelines for 
management of agitation among pediatric patients in the 
ED, including use of STAT (for immediate administration) 
or STAT/PRN medications, in follow up to the Consensus 
Statement of the American Association for Emergency 
Psychiatry (AAEP) Project BETA Psychopharmacology 
Workgroup guidelines for agitation in adults.10 
METHODS 
Study Design and Setting
Given the dearth of child psychiatrists in the U.S., this 
workgroup focused on the consensus of a group of experts 
in this subspecialty. The workgroup was assembled from 
experts in emergency child and adolescent psychiatry and 
psychopharmacology from the AAEP, the American Academy 
of Child and Adolescent Psychiatry (AACAP) Emergency 
Child Psychiatry Committee, and peer recommendation. 
Sixteen experts participated, all board certified in child and 
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adolescent psychiatry with some additionally board certified in 
pediatrics. The experts represented 14 hospitals in eight states.
Interventions
The non-voting project chair (RG) facilitated discussion, 
information gathering, and consensus building. Consensus 
was obtained using consensus development methodology, 
specifically the Delphi method, which was developed to obtain 
reliable opinion consensus and avoid bias.19-20 Per the Delphi 
method, opinions were elicited from the experts through a 
series of emailed questionnaires and structured solicitation 
of feedback. There were six rounds of questionnaires and 
feedback in total, starting with determining the structure of the 
guidelines (by age/weight, medication class, severity or etiology 
of agitation), and then narrowing progressively to choose 
the assessment strategies, etiologic categories, medications, 
doses, and cautions noted below. In the first of these rounds 
of questionnaires, experts assessed the standardized review of 
the existing literature on management of agitation summarized 
above, as well as published and unpublished guidelines and 
protocols used by EDs across the country (solicited through 
AAEP, AACAP, and outreach to several EDs and experts in the 
field). All opinions were anonymized and aggregated by the 
project chair to avoid direct confrontation between experts and 
prevent bias. This manuscript also underwent two rounds of 
workgroup feedback. 
RESULTS
The following summarizes the consensus recommendations 
for the evaluation and pharmacological management of 
agitation among pediatric patients in the ED.
Multimodal Approach 
There is consensus that management of agitation in the ED 
should be individualized, multidisciplinary, and collaborative. 
Medication should serve as one part of a comprehensive 
strategy to address the behavior. Clinicians should attempt 
to understand the etiologic factors leading to agitation, use 
non-pharmacologic de-escalation strategies, and choose 
medication based on the patient’s specific needs and history. 
For example, consider a child with autism who is brought to 
the ED for aggression triggered by anxiety, who then becomes 
agitated and attempts to flee the ED due to hunger and 
sensitivity to fluorescent lights. Effective treatment requires 
addressing his anxiety (considering non-pharmacologic and 
pharmacologic interventions), hunger, and sensory needs. In 
many cases, addressing etiologic factors proactively and non-
pharmacologically can obviate or completely eliminate the need 
for pharmacologic management. 
Etiology Drives Choice of Treatment  
There is consensus that, whenever possible, the etiology 
of agitation should be ascertained and all treatments targeted to 
the root causes of the agitation. Diagnostic assessment occurs in 
parallel with symptomatic management. Collateral information, 
response to non-pharmacologic interventions, mental status and 
change in symptoms over time inform this ongoing assessment. 
While standardized scales are often used in adult settings, 
there are few broadly used, evidence-based tools for pediatric 
agitation; thus, thoughtful clinical assessment is imperative. 
Cross-disciplinary collaboration and communication is also key 
to identifying potential causes of agitation. The bedside nurse is 
uniquely suited to notice changes in the patient’s mental status 
or behavior, implement non-pharmacologic strategies early, 
and quickly engage crisis services. Family members provide 
a crucial premorbid developmental and behavioral baseline of 
their child and may help elucidate the cause of agitation. 
The assessment of etiology starts with asking why the child 
has become agitated now and here, considering antecedents such 
as environmental or interpersonal triggers, as well as internal 
stressors such as pain or acute psychiatric symptoms. Psychiatric 
history, medication review, including any potential for toxic 
ingestion (intentional or accidental), allergies, past medical 
history, developmental history and a focused social and family 
history, including trauma history, should also be obtained.21
Medical evaluation of agitated patients is critical, although 
completing a full physical examination and any indicated 
laboratory/imaging studies may be challenging during acute 
agitation. If the etiology of agitation is unknown or mixed, there 
is consensus that the clinician should use best clinical judgment 
and provide symptomatic management based on available 
diagnostic and clinical information. The clinician should 
continuously reevaluate the differential diagnosis, observing 
response to intervention closely, and adjust diagnostic assessment 
and management accordingly.
Differential Diagnosis 
Agitation is a symptom, like pain, with many potential 
etiologies and often multiple factors contributing in the moment. 
The potential etiologies for acute agitation among youth in 
the ED includes physical disease (such as pain, delirium, 
intoxication and catatonia), anxiety, developmental and cognitive 
disabilities, behavioral disorders, trauma, mania, psychosis, 
sensory or physical limitations, and difficulty communicating 
needs. Even if a child has a known history of psychiatric or 
developmental disorders, comorbid physical disease, anxiety 
or other acute triggers should still be ruled out and a broad 
differential maintained. Non-pharmacologic approaches used 
for de-escalation should be employed early with a preventative, 
proactive approach. 
Non-pharmacologic Management
There is consensus that non-pharmacologic approaches 
should be used to prevent and de-escalate agitation before 
pharmacologic measures are considered. A multidisciplinary 
approach allows primary and secondary prevention strategies. 
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Primary prevention includes changes to the ED environment 
to make youth more comfortable, clear communication to 
reduce anxiety, and effective assessment and treatment of pain 
and other acute physical symptoms. Secondary prevention 
includes modifications for youth identified to be at baseline 
elevated risk for agitation or for youth beginning to show 
signs of agitation. Family members may identify calming 
strategies that have been effective in the past, which may 
contribute to crisis and behavioral planning. An agitated child 
should be moved away from other patients to a calming, safe 
area without access to sharps and dangerous objects.21 
Even if a youth in the ED is becoming highly agitated, 
simple non-pharmacologic de-escalation strategies can be 
effective and should always be attempted before, with, and after 
pharmacotherapy. Communicating in a neutral yet empathic 
tone, communicating at the patient’s eye level, and using 
clear, concrete and simple language (or visual communication 
tools for youth with developmental disabilities) are helpful. 
Reunification with (or separation from) family members, 
food, drink, distraction, preferred comfort items from home, 
or sensory coping kits can ease tension. Firm limits on 
unacceptable behaviors and specific praise for adherence to 
requests and de-escalation mold behavior while also modeling 
for families how to parent in the face of disruptive behaviors. 
Reflective statements and validation help youth who struggle 
with articulating complex emotions feel understood, while 
clarifying triggers for agitation and promoting problem-solving. 
Rationale for Medication Use
The goal of pharmacotherapy is twofold: 1) target 
the underlying cause of distress; and 2) calm the patient 
sufficiently for rapid assessment and treatment.
While medication for agitation is often considered 
when non-pharmacologic interventions have “failed,” 
pharmacologic and non-pharmacologic strategies should be 
used in concert with non-pharmacologic de-escalation efforts 
continuing during and after medication administration. When 
medication is used, it should be calming but not excessively 
sedating, as a youth who is asleep cannot be evaluated, 
participate in care, or leave the ED. Medication should be 
chosen for its calming effect but also to address the underlying 
etiology of the youth’s distress, so no one medication will be 
appropriate for all patients or all types of agitation.
General Recommendations Regarding Medication Use 
(Table 1, Table 2)
A current medication list and medication history 
(including prior STAT/PRN medication use) helps to avoid 
drug interactions and adverse drug events (ADEs) and inform 
medication choice and dosing. Often a half dose or extra dose 
of a home medication can ameliorate escalating agitation. There 
is neither firm evidence nor consensus to support the use of one 
medication or even class of medication for all patients. Risks 
of ADEs should be weighed against potential benefit, while 
considering patient age, weight, medical comorbidity, and 
development when choosing a medication. There is consensus 
that PO administration should be tried whenever possible before 
the IM route. If intravenous access is already in place and safely 
accessible, this is preferred to IM administration. Neuroleptics 
should be used judiciously, only when truly indicated, and 
with appropriate monitoring, given potential adverse effects, 
particularly extrapyramidal adverse effects. Response to any 
intervention should be observed and documented closely. 
Diphenhydramine, benzodiazepines, and alpha-2 agonists 
are generally calming and can also provide symptom-focused 
treatment. Diphenhydramine, with a more benign ADE profile 
and greater familiarity among families and medical providers, 
should be considered for younger children, youth with mild 
to moderate anxiety, youth with severe anxiety not secondary 
to delirium, intoxication, or withdrawal, and youth with mild 
agitation and no clear psychiatric or significant physical health 
history. Diphenhydramine and benzodiazepines should be 
avoided in delirium or in children where there is history of, 
or concern for, paradoxical disinhibition. Alpha-2 agonists 
can also provide symptomatic management of anxiety, 
hyperactivity, and hyperarousal, although these medications 
require blood pressure monitoring.22  
Neuroleptics can be considered for most causes of severe 
agitation. Total daily dose should be monitored closely. 
Olanzapine can potentially be more sedating than haloperidol 
or risperidone and has less risk for cardiac adverse events 
or extrapyramidal symptoms. Given the risk of respiratory 
suppression if given concomitantly with benzodiazepines, 
olanzapine and benzodiazepines should not be administered 
parenterally within one hour of each other.23 Despite the 
studies noted above of PRN ziprasidone for agitation in 
psychiatric inpatients, there is consensus that ziprasidone 
is not recommended due to its activating potential, QT 
prolongation risk, and need for concomitant food intake when 
administered PO.
There is consensus that if an initial dose of medication 
was ineffective, a second dose of the same medication 
is preferable to adding multiple different medications 
(unless limited by ADE), as children can be vulnerable to 
drug-interaction adverse effects. An exception to this was 
combining haloperidol and lorazepam, which was generally 
considered preferable to a second dose of a neuroleptic in 
non-delirious patients. The etiology of agitation should be 
reassessed continuously, especially after two doses of a 
particular medication, and youth who have received multiple 
doses should be monitored continuously. Total daily dose or 
not to exceed instructions should be written and cumulative 
doses monitored, lest akathisia, delirium, and iatrogenic 
syndromes such as neuroleptic malignant syndrome be 
misperceived as worsening agitation.
There is consensus that ketamine and barbiturates are 
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Medication factors
Formulas available
Onset and duration of action
Presence or absence of active metabolites
Interactions with other medications the patient has received in the ED or takes at home
Metabolism and exrcetion
Potential side effects or other drug effects that may be advantageous
Patient factors
Etiology or etiologies of agitation
Routes of administration available (PO, IV, IM, NGT)
GI function
Nutritional status and physical size
Hepatic function
Renal function
Other co-morbid physical health concerns
Desired response or effect on patient
Previous experience with psychotropics
Response to non-pharmacologic de-escalation strategies
Patient preference 
Family expectation and family preference
System factors
Training and experience with non-pharmacologic approaches to agitation management and with use of different medications for agitation
Comfort of other work providers with use, monitorind and management of a given medication
Availability of monitoring practices within the care setting and hospital system
ED, emergency department; PO, by mouth; IV, intravenous; GI, gastrointestinal; IM; intramuscular; NGT, nasogastric tube.
Table 1. Considerations when selecting a psychotropic for acute agitation management.
not recommended for treatment of agitation and that opioid 
analgesics should not be used for agitation unless for pain control.
Specific Guidelines for Medication Use (Figure)
Below are the consensus medication regimens for the 
five most common etiologies of agitation: delirium; substance 
intoxication/withdrawal; developmental disability-related; 
psychiatric diagnosis; and unknown ctiology. Youth may present 
with agitation of mixed etiology, for example an adolescent 
with bipolar disorder who presents intoxicated, or a child with 
autism spectrum disorder who is delirious secondary to medical 
illness. In such complex cases, the ED clinician should use his 
or her best judgment in assessing the relative contribution of 
each etiologic factor to the presentation and strongly consider 
consulting child and adolescent psychiatry or other pediatric 
subspecialists for assistance.
Agitation Due to Delirium 
Delirium is a complex clinical syndrome in which 
underlying physical disease, pharmacologic factors or both 
cause acute onset of mental status change with fluctuating 
course, involving symptoms of inattention, altered level of 
awareness and other cognitive deficits.24 Management of delirium 
requires identification and treatment of underlying etiologies. 
The initial approach should include reduction or discontinuation 
of medications that may be causing or exacerbating delirium. 
Pain should be treated while avoiding over-sedation and limiting 
exposure to opioid analgesia, which can worsen delirium. 
Medications may be needed to address underlying etiologies 
potentiating delirium, support sleep, and ameliorate physical 
symptoms such as pain or nausea. Medication for agitation can 
be necessary for safety, as well as avoiding medications that may 
worsen confusion or behavior in the setting of delirium, namely 
anticholinergics, benzodiazepines, and opioid analgesics.
Neuroleptics are the most commonly used 
pharmacologic intervention for delirium. Second-generation 
neuroleptics such as risperidone, olanzapine, and quetiapine 
have eclipsed haloperidol as the first-line agents.25-27 Choice 
of neuroleptic should account for the patient’s particular 
needs including route of administration, time to effect, 
potential side effects, illness factors, patient past experience 
with neuroleptics, and the specific symptoms of delirium 
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being targeted. Clonidine may be used if there is reason 
to avoid neuroleptics. Melatonin may be helpful for sleep 
regulation if this is contributing to agitation.
Agitation Due to Substance Intoxication or Withdrawal 
In cases of known or suspected substance intoxication or 
withdrawal, medication choice should be dictated by clinical 
presentation and the suspected substances. If urine toxicology 
is indicated, and the results are negative, newer synthetic drugs, 
such as synthetic cannabinoids and cathinones, should be 
suspected. Gas chromatography and mass spectrometry, where 
available, can also help to identify an ingestion. If the substance 
ingested is unknown, there is consensus that lorazepam should be 
used, and potentially combined with haloperidol if the patient is 
severely agitated or hallucinating. 
Agitation in a Patient with Developmental Delay or Autism 
Spectrum Disorder 
Youth with autism or developmental disabilities can 
be particularly vulnerable to ADEs from many of the 
medications commonly used to treat acute agitation, including 
benzodiazepines. Therefore, behavioral strategies are 
especially important in this population. Youth with autism or 
developmental disabilities often become agitated in the context 
of unrecognized physical or sensory discomfort, including 
headache, dental pain, gastrointestinal distress/constipation, and 
overstimulation. A detailed history from parents or guardians 
and close observation/examination can often elucidate potential 
triggers and inform treatment. A care plan with a list of specific 
triggers and calming strategies helps coordinate care across 
shifts in the ED setting. Asking parents or guardians about the 
child’s prior medication responses, either positive or negative, 
can also inform choice of PRN medication. An extra dose of 
the child’s regular standing medication may be preferable given 
risk of ADEs. IM administration should be avoided unless 
absolutely necessary for safety. 
Agitation in the Context of Acute Psychiatric Illness 
Agitation can occur in youth with a range of psychiatric 
illnesses, both acute and chronic. Missing home medications, 
at times due to waiting in the ED, is a frequent cause of 
agitation, so administering those home medications or 
administering an extra half or full dose can be effective. Youth 
with chronic psychiatric illness may alternatively become 
agitated for reasons that have nothing to do with their illness 
(e.g., a teen with a history of bipolar mania who is delirious, 
intoxicated, or in severe pain). Clinicians should also recall 
that mania and psychosis are rare in preadolescents; thus, a 
child presenting with agitation with disorganized thinking/
behavior, hallucinations or delusions is more likely to be 
delirious, catatonic, or having difficulty communicating his 
or her experiences due to autism, intellectual disability, or 
psychological trauma. 
Agitation of Unknown Etiology
While every effort should be made to identify the etiology 
of agitation, there will be patients for whom this is not possible, 
and the clinician should use his or her best judgment. For mild 
agitation, de-escalation strategies should be used while triggers 
for agitation are assessed. For moderate agitation, lorazepam, 
diphenhydramine or olanzapine can be used (though olanzapine 
and lorazepam should not be co-administered). For severe 
agitation, lorazepam can be combined with haloperidol, or 
chlorpromazine, or olanzapine can be used as single agents. 
DISCUSSION
While there was consensus as to general principals of 
medication use for agitation and some specific agents and 
strategies as described above, there was not consensus to 
support the use of one medication or even class of medication 
for all patients. This reflects both the absence of a strong 
evidence base, heterogeneity of the patient population, 
multifactorial nature of agitation, and practice differences 
between hospitals, regions, training programs, and individuals. 
The specific ED setting will also have significant 
influence on choice of medication for agitation, and even 
on when medications are indicated. In the situation of 
an unlocked medical ED containing numerous pieces 
of equipment with which a child could (purposefully or 
accidentally) harm himself or herself or others, it may be 
faster to medicate an agitated child than in a psychiatric ED 
with specialized staff and an environment designed for safety. 
Psychiatric EDs, however, rarely have child life support 
that can be crucial in preventing agitation among young or 
developmentally-delayed children in a pediatrics ED. Medical 
or pediatric EDs can administer IV medications compared 
to psychiatric EDs, which typically use IM medications if 
PO is not possible. Medical EDs may be more comfortable 
with potential ADEs such as QT prolongation or respiratory 
suppression if they have rapid or routine access to telemetry or 
airway support, but may balk at using unfamiliar psychiatric 
medications like chlorpromazine. Psychiatric EDs often 
lack immediate access to pediatric or emergency medicine 
support, which may complicate assessment and management 
of delirium or catatonia secondary to physical illness. Hospital 
formulary, tradition, and milieu preferences will also influence 
medication choice. 
While these consensus guidelines are written largely with 
psychiatrists and child psychiatrists in mind, they are informed 
by expert consensus from providers with training in pediatrics 
and consultation psychiatry. We anticipate these guidelines 
may also be of use to pediatricians and EPs working in ED 
settings without immediate access to psychiatry consultation. 
When available, psychiatric consultants can help elucidate the 
etiology of agitation. Psychiatric consultation can also assist 
with the choice of medication and ongoing non-pharmacologic 
de-escalation strategies. Especially if a first dose of medication 
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for an agitated child was not effective, psychiatry should 
be consulted to reevaluate the differential diagnosis and 
the pharmacologic and non-pharmacologic treatment plan. 
Psychiatry consultation should also be obtained for patients 
with more complex psychiatric pathology and those who are on 
complex regimens already, patients with a history of paradoxical 
reaction to medication, and patients with agitation of mixed 
etiology. Involvement of other mental health providers, including 
psychologists and social work, can be helpful in the diagnostic 
assessment as well as implementation of non-pharmacologic 
management strategies. 
LIMITATIONS
This report describes the results of expert consensus 
guidelines for psychopharmacologic management of agitation 
among pediatric patients in the ED. These guidelines are 
based on a systematic review of the literature, a review of 
existing guidelines and hospital protocols, and utilization of 
an accepted and evidence-based, consensus generation process 
designed to reduce bias. However, these guidelines are still 
predominantly based on expert opinion. They have not been 
tested for efficacy either in isolation or in comparison to 
existing guidelines or hospital protocols. 
CONCLUSION
In summary, while agitation in the ED occurs frequently 
and with high costs to patients and clinical programs, there is 
vastly insufficient research into the understanding, prevention, 
assessment or treatment of agitation in this context. Further 
research is needed in many areas of pediatric emergency 
psychiatry, and especially into the comparative efficacy of 
different medications for agitation in different types of patients, 
and into the efficacy of these medications compared to placebo 
or to non-pharmacologic de-escalation strategies.28-29 ED 
nursing and staff, pediatricians, emergency physicians, and adult 
psychiatrists need training in rapid diagnosis and stabilization 
of agitated youth, as well as support for non-pharmacologic 
de-escalation and crisis management. Computerized/electronic 
medical record-based assessment and risk stratification tools 
may be useful, as may be clinical pathways directed at providing 
support and ancillary services (child life, psychiatric, or social 
work consult) to at-risk youth before agitation occurs.
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